• Secura Bio Acquires Global Rights To Farydak® pharmafocusasia
    March 13, 2019
    Secura Bio, Inc., an integrated, commercial-stage biopharmaceutical company dedicated to the worldwide commercialization of significant oncology therapies, today announced that it has acquired the global rights to Farydak® (panobinostat) from Novartis.
PharmaSources Customer Service